Newsletter
Newsletter Support JNS

Israel becomes first country in world to perform ‘artificial meniscus’ transplant

“This is an exciting time to finally put the NUsurface implant at the disposal of Israeli patients. Persistent pain after repair of meniscus tears is a very common orthopedic problem and, until now, we did not have effective treatment options,” said Dr. Gabriel Agar.

Israeli surgeons perform the artificial meniscus implant on Nov. 11, 2019. Credit: Active Implants LLC.
Israeli surgeons perform the artificial meniscus implant on Nov. 11, 2019. Credit: Active Implants LLC.

The world’s first successful “artificial meniscus” transplant was just performed in Israel, i24News reported on Monday.

The surgery was performed by Dr. Gabriel Agar from the Yitzhak Shamir Medical Center in Be’er Ya’akov and Dr. Ron Arbel from Ramat Aviv Medical Center in Tel Aviv, who were both involved in the development of the “NUsurface Implant,” which passed clinical trials in Israel and is made from medical-grade plastic in Israel by Active Implants LLC.

It was given a Breakthrough Device Designation by the U.S. Food and Drug Administration.

The implant is inserted into the knee joint with a small incision and made to mimic the movement of the body’s natural meniscus. It does not require any fixation on the bones or soft tissues, which allows patients to return home not long after the operation is complete.

Patients with damaged or torn menisci can have the transplant surgery as a replacement for previous treatments, such as pain management and physical therapy, according to i24News.

The Jerusalem Post noted that the implant is “intended for people who have regular knee pain following medial meniscus surgery; have failed meniscus repair; are not suitable candidates for a meniscus allograft transplant; or are too young for knee replacement.”

Agar said “this is an exciting time to finally put the NUsurface implant at the disposal of Israeli patients. Persistent pain after repair of meniscus tears is a very common orthopedic problem and, until now, we did not have effective treatment options.”

The deliberate targeting by Tehran and by its proxy Hezbollah of civilian areas in Israel and in other neighboring states violates all humanitarian norms and is absolutely prohibited.
“It’s a great victory for the First Amendment right to free speech, including the right to draw attention to bigotry and hateful speech,” Paul Eckles, of the Brandeis Center, told JNS. “We commend our client for having the courage to speak out.”
U.S. President Donald Trump appears to have precipitated the move by demanding congressional action in a social media post earlier on Wednesday.
JNS sought comment from Aria Fani and received an autoreply, “On leave until September. Will not check email with capitalist frequency.”
A spokesman for the Ivy told JNS that the school believes being required “to create lists of Jewish faculty and staff, and to provide personal contact information, raises serious privacy and First Amendment concerns.”
The new program adds “America First foreign policy lectures” and shifts focus to merit and core diplomatic skills.